Press Release · APEC China 2026
United Family Healthcare Founder Highlights Cross-Border Medical Cooperation and Pharmaceutical Innovation Ahead of 2026 APEC Meeting in Shenzhen
Distributed by Insights Emerge · Originally issued via Newswire

BEIJING, November 19, 2026 (Newswire.com) - APEC China 2026 today highlighted insights from Roberta Lipson, founder of United Family Healthcare and Chair Emeritus of the American Chamber of Commerce in China, addressing how healthcare delivery, clinical research partnerships, and pharmaceutical innovation strengthen bilateral cooperation between China and the United States ahead of the 2026 APEC Economic Leaders' Meeting in Shenzhen. In remarks examining nearly five decades of healthcare development in China, Lipson highlighted how joint medical education, hospital partnerships, and cross-border clinical investment foster institutional trust and shared progress across Asia-Pacific economies.
Arriving in Beijing in 1979, Lipson has spent nearly 50 years working within China's healthcare sector, observing large-scale demographic and public health transformations. According to data cited in her assessment, China's average life expectancy has more than doubled since 1949 to reach nearly 80 years in 2025, while infant and maternal mortality rates have declined nearly tenfold alongside the expansion of national health insurance coverage and public safety-net programs. Lipson noted that sustained economic growth, improved nutrition, and long-term public health frameworks-including the Healthy China 2030 initiative-have supported broad improvements in clinical infrastructure and patient access.
A central focus of Lipson's commentary centers on bilateral clinical collaboration between Chinese and United States medical institutions. Through physician training exchanges, joint biomedical research programs, and hospital joint ventures, healthcare providers from both countries have built operational frameworks that serve domestic and international patient populations. At United Family Healthcare facilities, medical practitioners from China, the United States, and multiple partner nations collaborate to treat patients representing China and more than 120 countries, demonstrating how clinical teams maintain shared professional standards and cross-cultural coordination.
Lipson also examined China's expanding role within the global biopharmaceutical and clinical research landscape. As the world's second-largest healthcare market, China has transitioned from generic manufacturing toward original drug discovery in therapeutic areas including oncology, immunology, and metabolic disorders. Industry figures referenced in the briefing indicate that Chinese pharmaceutical developers executed international out-licensing agreements exceeding $130 billion in 2025, representing a record volume of cross-border commercial partnerships. Additionally, China-based research sponsors accounted for 39 percent of global oncology clinical trial starts over the past year, reflecting increased clinical trial capacity and regulatory alignment.
According to Lipson, domestic availability of novel therapies and streamlined clinical scheduling are increasingly drawing international patients seeking specialized medical care. Certain domestically developed biologics and cellular therapies have entered clinical use in China prior to commercial rollout in other jurisdictions. Citing chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies as a benchmark, Lipson noted that treatment costs in China range from approximately $150,000 to $230,000, compared with more than $550,000 in the United States. Furthermore, surgical and specialist treatment timelines in major Chinese medical centers frequently span days or one to two weeks following diagnosis, whereas procedural wait times in parts of North America and Europe can extend across several months. Beyond oncology, Lipson identified healthy longevity and regenerative medicine as emerging sectors for bilateral research and clinical investment, supported by Beijing's biomedical institutes and tertiary hospital networks.
Addressing broader commercial dynamics, Lipson pointed to survey findings from the American Chamber of Commerce in China and the US-China Business Council demonstrating continued corporate commitment to bilateral engagement. More than half of surveyed AmCham China member companies rank China among their top three global investment priorities, while over 83 percent report that a stable and constructive US-China relationship remains critical to commercial operations and global supply chain continuity.
While identifying healthcare, environmental stewardship, and trade facilitation as practical channels for regional cooperation during the 2026 APEC meetings in Shenzhen, Lipson acknowledged regulatory areas requiring sustained intergovernmental coordination. Specifically, she noted that cross-border clinical data governance, artificial intelligence safety standards in healthcare, and international genetic research protocols require transparent policy dialogue across Asia-Pacific economies.
"Healthcare addresses universal human needs and creates durable channels for professional trust even when nations navigate complex economic or policy differences," said Roberta Lipson, Founder of United Family Healthcare and Chair Emeritus of the American Chamber of Commerce in China. "Sustaining people-to-people exchanges among clinicians, researchers, and healthcare institutions strengthens patient outcomes across both countries while supporting broader regional stability ahead of the 2026 APEC Economic Leaders' Meeting."
Video reference: https://www.youtube.com/watch?v=AXZ-TKURDIc
Media Contact Details
Apec China
APEC China 2026
[email protected]
www.apec2026.cn/index.html
SOURCE: APEC China 2026
Source: APEC China 2026
Related Media
About APEC China 2026
APEC China 2026 serves as the official host platform for the Asia-Pacific Economic Cooperation (APEC) meetings convened across China in 2026 under the theme "Building an Asia-Pacific Community to Prosper Together." Coordinating ministerial dialogues and economic summits across host cities including Shenzhen, Beijing, Shanghai, Guangzhou, Hong Kong SAR, and Macao SAR, APEC China 2026 advances regional policy alignment, digital connectivity, supply chain resilience, and sustainable economic cooperation across Asia-Pacific member economies. Additional information is available at APEC China 2026.